Cribstone Capital Management’s Quest Diagnostics DGX Stock Holding History

Cribstone Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-336	Closed	-$36K	–	412
2019 Q3	$36K	Hold	336	–	–	0.02%	258
2019 Q2	$34K	Hold	336	–	–	0.02%	282
2019 Q1	$30K	Buy	336 +28	+9%	+$2.43K	0.02%	311
2018 Q4	$26K	Buy	308 +265	+616%	+$24.8K	0.01%	336
2018 Q3	$5K	Hold	43	–	–	﹤0.01%	606
2018 Q2	$5K	Hold	43	–	–	﹤0.01%	610
2018 Q1	$4K	Sell	43 -3	-7%	-$307	﹤0.01%	630
2017 Q4	$5K	Hold	46	–	–	﹤0.01%	663
2017 Q3	$4K	Buy	46 +6	+15%	+$637	﹤0.01%	616
2017 Q2	$4K	Hold	40	–	–	﹤0.01%	610
2017 Q1	$4K	Sell	40 -46	-53%	-$4.38K	﹤0.01%	634
2016 Q4	$8K	Sell	86 -39	-31%	-$3.36K	﹤0.01%	519
2016 Q3	$10K	Buy	125 +26	+26%	+$2.18K	0.01%	502
2016 Q2	$8K	Buy	+99	New	+$7.54K	﹤0.01%	551

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cribstone Capital Management's DGX Position: Q4 2019 in Review

Cribstone Capital Management sold out of Quest Diagnostics (DGX) in Q4 2019, closing a stake of 336 shares — an estimated $36K sold.

Cribstone Capital Management first reported a position in DGX in Q2 2016 and held it in 14 quarters. The position peaked at $36K in Q3 2019. 711 funds tracked by Wall St. Rank hold DGX as of Q4 2019.

Cribstone Capital Management reported no remaining Quest Diagnostics position as of Q4 2019 after selling out during the quarter.
Cribstone Capital Management sold 336 Quest Diagnostics shares in Q4 2019, an estimated $36K.
Cribstone Capital Management first reported a position in Quest Diagnostics in Q2 2016 and held it in 14 quarters.
Cribstone Capital Management's Quest Diagnostics position peaked at $36K in Q3 2019.
711 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2019.

Based on Cribstone Capital Management's 13F filing for Q4 2019, filed 8 Jan 2020.